---
title: "Telemedicine and At-Home Ketamine: Setting Up a Remote Treatment Program"
slug: "telemedicine-ketamine-protocols"
excerpt: "A comprehensive operational guide for practitioners establishing telemedicine-based ketamine programs, covering regulatory requirements, patient selection criteria, remote monitoring protocols, technology infrastructure, and safety considerations for at-home treatment."
category: "PRACTICE_MANAGEMENT"
author: "Ketamine Association Editorial Team"
publishedAt: "2026-01-08"
featuredImage: "/images/articles/placeholder.jpg"
tags: ["practitioners", "ketamine", "business", "telemedicine", "at-home-treatment", "remote-care"]
audience: "practitioners"
---

# Telemedicine and At-Home Ketamine: Setting Up a Remote Treatment Program

The convergence of telemedicine expansion and ketamine therapy growth has created a new treatment paradigm: supervised at-home ketamine treatment. Accelerated by the pandemic-era relaxation of telehealth regulations, this model has evolved from necessity to a legitimate treatment option that expands access for patients who cannot easily attend in-person clinics. However, at-home ketamine treatment introduces complexities that require careful protocol development, robust monitoring systems, and rigorous patient selection. This article provides a comprehensive framework for practitioners considering or operating remote ketamine treatment programs.

## The At-Home Ketamine Landscape

### Current State of Practice

At-home ketamine treatment has grown significantly:

**Treatment Models**:
- Sublingual/oral ketamine prescribed with telehealth supervision
- Intranasal ketamine (not Spravato, which requires in-person REMS)
- Telehealth-supervised sessions with home-delivered medication
- Hybrid models with initial in-person treatment followed by home maintenance

**Market Development**:
- Multiple national telemedicine ketamine companies have emerged
- Traditional brick-and-mortar clinics adding telemedicine components
- Significant variation in protocols, oversight, and quality

### Regulatory Landscape

The regulatory framework for telemedicine ketamine is evolving:

**Federal Regulations**:
- DEA prescribing requirements for controlled substances via telehealth
- Ryan Haight Act and its pandemic-era modifications
- Ongoing policy discussions about permanent telehealth flexibilities

**State Requirements**:
- Medical licensing in patient's state
- State-specific telemedicine practice standards
- Prescribing requirements for controlled substances
- Corporate practice of medicine considerations

**Key Regulatory Considerations**:

| Issue | Requirement |
|-------|-------------|
| Physician Licensing | Must be licensed in patient's state |
| In-Person Requirements | Vary by state; some require initial in-person visit |
| Controlled Substance Rx | State-specific rules on telemedicine prescribing |
| Supervision Requirements | Medical director and supervising physician requirements |
| Pharmacy Regulations | Compounding pharmacy licensing and shipping |

**Important**: The DEA Special Telemedicine Registration process and permanent telehealth rules for controlled substances continue to evolve. Practitioners must monitor regulatory developments and adjust protocols accordingly.

## Patient Selection for Remote Treatment

### Inclusion Criteria

Not all patients appropriate for ketamine therapy are appropriate for at-home treatment:

**Strong Candidates for At-Home Treatment**:
- Established response to ketamine (previous in-person treatment)
- Stable psychiatric condition
- Reliable, engaged patient with good insight
- Appropriate home environment
- Reliable internet/phone connectivity
- Available support person for sessions
- Geographic barriers to in-person care
- Physical disabilities making travel difficult

### Exclusion Criteria

**Absolute Contraindications for At-Home Treatment**:
- Active suicidal ideation with intent or plan
- Active psychosis
- Uncontrolled hypertension
- History of severe adverse reactions to ketamine
- Active substance use disorder (especially dissociatives)
- Inability to arrange appropriate supervision
- Lives alone without support person availability
- History of treatment non-compliance

**Relative Contraindications**:
- Treatment-naive patients (consider in-person initiation)
- Significant cardiovascular disease
- Limited insight or psychological mindedness
- History of medication misuse or diversion
- Complex psychiatric comorbidity
- Inadequate technology access

### Risk Stratification Framework

```
Low Risk (Appropriate for At-Home)
├── Previous successful in-person ketamine treatment
├── Stable on maintenance protocol
├── PHQ-9 < 15, no suicidal ideation
├── Reliable support person
├── Good medication adherence history
└── Appropriate home environment

Moderate Risk (Consider With Enhanced Protocols)
├── Treatment-naive but thorough evaluation completed
├── Moderate depression without suicidality
├── Support person available but not for every session
├── Minor cardiovascular risk factors (controlled)
└── Some technology limitations

High Risk (In-Person Treatment Recommended)
├── Active suicidal ideation
├── Severe depression (PHQ-9 > 20)
├── Significant cardiovascular disease
├── No support person available
├── History of adverse reactions
└── Concerns about compliance or diversion
```

### Intake and Evaluation Process

**Initial Evaluation Components**:

1. **Comprehensive Psychiatric Assessment** (via telehealth)
   - Diagnostic evaluation
   - Treatment history
   - Medication review
   - Suicidality assessment (C-SSRS)
   - Substance use screening

2. **Medical Evaluation**
   - Review of medical history
   - Current medications
   - Cardiovascular risk assessment
   - Required laboratory work
   - Primary care provider communication

3. **At-Home Suitability Assessment**
   - Home environment evaluation
   - Support person availability and willingness
   - Technology capability
   - Understanding of treatment requirements
   - Medication storage and safety

4. **Informed Consent**
   - Treatment risks and benefits
   - At-home specific considerations
   - Emergency protocols
   - Medication handling requirements
   - Follow-up requirements

## Remote Monitoring Protocols

### Synchronous Monitoring (Real-Time)

**Video Supervision Requirements**:
- Minimum: Video supervision from 15 minutes pre-dose through peak effects
- Recommended: Video supervision throughout entire session (60-90 minutes)
- Camera positioned to show patient's face and body
- Provider or trained staff member monitoring throughout

**Vital Signs Monitoring Options**:

| Method | Advantages | Limitations |
|--------|-----------|-------------|
| Self-reported | Simple, no equipment | Accuracy concerns |
| Automated BP cuff | Objective data | Requires equipment, patient operation |
| Bluetooth devices | Real-time transmission | Technology complexity |
| Pulse oximetry | Continuous monitoring | Additional cost |

**Minimum Monitoring Protocol**:
- Blood pressure: Baseline, 15 minutes, 30 minutes, and before session end
- Heart rate: Same intervals
- Subjective distress level: Every 15 minutes
- Video observation: Throughout session

**Enhanced Monitoring Protocol**:
- Continuous video monitoring with active provider engagement
- Bluetooth-enabled BP cuff with automatic transmission
- Pulse oximeter throughout session
- Support person present with emergency training

### Asynchronous Monitoring

**Between-Session Monitoring**:
- Daily symptom tracking (PHQ-9/PHQ-2)
- Medication compliance verification
- Side effect assessment
- Substance use screening
- Weekly provider check-in (phone or video)

**Technology Platforms**:
- Patient portal for symptom entry
- Automated screening prompts
- Provider dashboard for monitoring
- Alert systems for concerning responses

### Emergency Protocols

**Pre-Session Planning**:
1. Confirm patient location and address
2. Identify nearest emergency department
3. Verify support person presence and training
4. Confirm patient's phone is charged and accessible
5. Review emergency protocol with patient and support person

**Emergency Response Protocol**:

```
Level 1: Mild Distress
├── Verbal reassurance
├── Grounding techniques
├── Dose may continue with monitoring
└── Document and follow up

Level 2: Moderate Distress/Vital Sign Changes
├── Consider early session termination
├── Support person engagement
├── Vital signs every 5 minutes
├── Provider remains on video until stable
└── Consider in-person follow-up

Level 3: Severe Reaction/Medical Emergency
├── Instruct support person to call 911
├── Provider stays on line with support person
├── Provide address and relevant history to EMS
├── Document thoroughly
└── Mandatory in-person evaluation before any future treatment
```

**Support Person Training**:
- Recognition of concerning symptoms
- How to call for emergency assistance
- Basic supportive techniques
- When to intervene vs. wait
- Documentation of their contact information

## Technology Requirements

### Platform Requirements

**Telehealth Platform Must-Haves**:
- HIPAA-compliant video conferencing
- Reliable connection quality
- Recording capability (with consent)
- Integration with EHR
- Patient-friendly interface
- Mobile accessibility

**Recommended Features**:
- Vital signs integration
- Symptom tracking dashboards
- Automated scheduling
- Secure messaging
- Patient portal for forms/consent
- Analytics and reporting

### Patient Technology Requirements

**Minimum Requirements**:
- Smartphone, tablet, or computer with camera
- Reliable internet connection (recommend speed test)
- Blood pressure cuff (provided or purchased)
- Phone accessible during session

**Recommended Setup**:
- Dedicated quiet space for sessions
- Camera positioned for full visibility
- Bluetooth-enabled monitoring devices
- Backup contact method

### Technology Support

**Patient Onboarding**:
- Technology test session before first treatment
- Written instructions for platform use
- Technical support contact
- Troubleshooting guide
- Backup plan for technology failure

## Medication Management

### Formulation Options

**Sublingual/Oral Ketamine**:
- Most common for at-home use
- Compounded by specialty pharmacies
- Typical forms: Lozenges (troches), rapid dissolving tablets, liquid
- Dose range: 100-400mg per session depending on formulation

**Intranasal Ketamine**:
- Compounded nasal spray
- More predictable absorption than sublingual
- Requires proper administration technique
- Not to be confused with Spravato (esketamine), which requires REMS

### Prescribing Considerations

**Initial Prescription**:
- Limited quantity (typically one week to one month)
- No refills until follow-up completed
- Clear instructions for use
- Storage requirements (secure location, away from others)

**Ongoing Prescriptions**:
- Based on compliance and response
- Regular reassessment required
- Pill/dose counts as appropriate
- Pharmacy dispensing directly to patient

### Pharmacy Relationships

**Selecting a Compounding Pharmacy**:
- Licensed in relevant states
- Experience with ketamine compounding
- Quality control procedures
- Shipping capabilities
- Pricing transparency
- Communication with providers

**Prescription Transmission**:
- Electronic prescribing where permitted
- Secure communication of patient information
- Tracking of dispensing
- Coordination of refills

### Preventing Misuse and Diversion

**Structural Safeguards**:
- Limited quantities prescribed
- Required video supervision for each dose
- Medication logs maintained by patient
- Random pill/dose counts
- Pharmacy dispensing records review

**Behavioral Red Flags**:
- Requests for early refills
- "Lost" medication
- Reluctance to have support person present
- Skipping follow-up appointments
- Requests for specific formulations or doses
- Sessions that don't match medication quantities

**Response to Concerns**:
1. Document specific concerns
2. Direct conversation with patient
3. Consider returning to in-person treatment
4. Discontinue treatment if diversion suspected
5. Report as required by regulations

## Operational Protocols

### Session Workflow

**Pre-Session (Day Before)**:
1. Automated reminder to patient
2. Confirm support person availability
3. Verify medication on hand
4. Review any interval symptoms
5. Confirm technology readiness

**Session Day (Pre-Dose)**:
1. Video connection established
2. Support person introduced to provider
3. Baseline vital signs obtained
4. Mood/symptom assessment
5. Review emergency protocol
6. Patient takes medication on camera

**During Session**:
1. Continuous video monitoring
2. Vital signs at regular intervals
3. Provider available for verbal support
4. Document observations
5. Support person present in home

**Post-Session**:
1. Final vital signs
2. Assessment of resolution of acute effects
3. Post-session instructions reviewed
4. Follow-up appointment confirmed
5. Emergency contact information re-confirmed

### Documentation Requirements

**Each Session Must Document**:
- Pre-treatment assessment
- Vital signs (all measurements)
- Dose administered
- Duration of observation
- Patient response and any adverse effects
- Support person presence
- Post-treatment assessment
- Plan and follow-up

**Regulatory Compliance Documentation**:
- State-specific telehealth documentation requirements
- Controlled substance prescribing documentation
- PDMP checks as required
- Patient location at time of service

### Quality Assurance

**Ongoing Quality Monitoring**:
- Regular protocol adherence audits
- Adverse event tracking
- Patient satisfaction surveys
- Outcome measurement
- Peer review processes

**Key Quality Metrics**:
- Percentage of sessions with complete documentation
- Adverse event rate
- Emergency intervention rate
- Patient retention
- Clinical outcomes (standardized measures)

## Building Your Remote Program

### Program Development Phases

**Phase 1: Foundation (Months 1-3)**
- Regulatory research and compliance planning
- Technology platform selection
- Protocol development
- Staff training
- Pharmacy relationships established
- Initial patient selection criteria

**Phase 2: Pilot (Months 4-6)**
- Limited patient enrollment (5-10 patients)
- Intensive monitoring and feedback
- Protocol refinement
- Technology troubleshooting
- Staff competency development

**Phase 3: Expansion (Months 7-12)**
- Gradual patient volume increase
- Workflow optimization
- Additional staff as needed
- Marketing and referral development
- Quality metric tracking

**Phase 4: Maturity (Year 2+)**
- Full operational capacity
- Continuous quality improvement
- Outcome data analysis and publication
- Protocol updates based on evidence

### Staffing Requirements

**Clinical Team**:
- Medical director (physician oversight)
- Treating providers (physicians, NPs, PAs as state allows)
- Monitoring staff (trained to observe sessions)
- Mental health support (therapists for integration)

**Operational Team**:
- Program coordinator
- Patient onboarding specialist
- Technical support
- Billing/administrative support

**Training Requirements**:
- Ketamine therapy fundamentals
- Telemedicine best practices
- Emergency response protocols
- Technology platform proficiency
- Regulatory compliance
- Documentation standards

### Financial Considerations

**Revenue Model**:
- Session fees (telehealth evaluation + treatment supervision)
- Consultation fees
- Medication costs (typically separate, paid to pharmacy)
- Monitoring/support services

**Cost Considerations**:
- Technology platform subscriptions
- Staff time for monitoring (significant)
- Medical director oversight
- Compliance and legal
- Marketing and patient acquisition

**Insurance Considerations**:
- Telehealth reimbursement varies by payer
- Mental health parity implications
- Out-of-network considerations
- Proper coding for telehealth services

## Risk Management

### Malpractice Considerations

**Insurance Requirements**:
- Verify malpractice coverage extends to telehealth
- Verify coverage in all states where practicing
- Consider additional coverage for controlled substance prescribing
- Document coverage for at-home treatment specifically

**Risk Mitigation Strategies**:
- Rigorous patient selection
- Comprehensive informed consent
- Thorough documentation
- Established emergency protocols
- Regular protocol review
- Quality improvement processes

### Compliance Program

**Elements of a Compliance Program**:
1. Designated compliance officer
2. Written policies and procedures
3. Regular training
4. Monitoring and auditing
5. Response to detected issues
6. Clear reporting mechanisms

**Areas Requiring Ongoing Compliance Monitoring**:
- State licensing and telehealth regulations
- DEA requirements and telehealth prescribing rules
- HIPAA and privacy
- State medical board standards
- Pharmacy and compounding regulations

## Case Example: Program Implementation

**Practice Profile**: Established ketamine clinic with 3-year history, 2 physicians, 500+ patients treated in-person.

**Rationale for Telemedicine Expansion**: Geographic barrier complaints from patients, maintenance patients seeking convenience, competitive pressure.

**Implementation Timeline**:

*Month 1-2*:
- Regulatory research for home state and neighboring states
- Platform evaluation and selection
- Protocol drafting based on professional guidelines
- Legal review of proposed program

*Month 3*:
- Staff training (full team)
- Technology testing
- Pharmacy relationship established
- Patient selection criteria finalized
- Marketing materials developed

*Month 4-5*:
- Pilot launch with 8 existing maintenance patients
- Weekly team debriefs
- Protocol refinement
- Documentation template optimization

*Month 6-12*:
- Gradual expansion to 25 patients
- New patient enrollment (treatment-naive with enhanced protocols)
- Workflow optimization
- First quality review completed

*Year 2*:
- 50+ active at-home patients
- Expanded to 3 states
- Outcome data published
- Model replicated by other practices

## Strategic Takeaways

1. **Start with In-Person**: At-home ketamine works best for established patients. Consider requiring initial in-person evaluation and treatment before transitioning to home-based care.

2. **Patient Selection is Critical**: Rigorous selection criteria prevent most adverse outcomes. Err on the side of caution, especially early in program development.

3. **Invest in Monitoring Infrastructure**: Real-time video supervision with vital signs monitoring is the foundation of safe at-home treatment. Cut corners here at significant risk.

4. **Require Support Persons**: Do not conduct at-home sessions without a trained support person present. This is non-negotiable for safety.

5. **Document Extensively**: Telemedicine documentation requirements are stringent. Build documentation workflows that capture all required elements.

6. **Stay Current on Regulations**: The regulatory landscape for telemedicine controlled substance prescribing continues to evolve. Monitor DEA and state-level developments closely.

7. **Quality Over Volume**: Growing too fast compromises safety. Prioritize program quality and patient outcomes over patient volume.

8. **Build Pharmacy Relationships**: Reliable compounding pharmacies are essential partners. Invest in these relationships.

9. **Plan for Emergencies**: Every session should begin with confirmed emergency protocols. The one time you need it will justify all the preparation.

10. **Consider Hybrid Models**: The strongest programs often combine in-person and telemedicine elements, using each modality where it's most appropriate.

## References

Greenhalgh T, et al. (2020). Video consultations for COVID-19. BMJ, 368, m998.

Krystal JH, et al. (2019). Ketamine and the future of rapid-acting antidepressants. Current Neurology and Neuroscience Reports, 19(4), 23.

DEA. (2023). Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act. Federal Register.

American Psychiatric Association. (2020). Best Practices in Videoconferencing-Based Telemental Health.

Federation of State Medical Boards. (2022). Telemedicine Policies Board by Board Overview.

Wilkinson ST, et al. (2019). A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. American Journal of Psychiatry, 176(9), 662-670.

*Note: Regulatory requirements for telemedicine and controlled substance prescribing vary by state and continue to evolve. Consult with healthcare legal counsel for guidance specific to your practice location and circumstances.*
